Another study shows that miR-33a inhibits proliferation and promotes differentiation of non-small cell lung cancer cells (NSCLCs) by binding to the 3′UTR of METTL3 [36], which suggests that METTL3 may be a novel therapeutic target for NSCLC. This evidence concerns the gene METTL3 and non-small cell lung carcinoma.